WGS at a glance
GeneDx Holdings Corp. (WGS, SEC CIK 1818331) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 18, 2026 and Form 4 insider filings as recently as September 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), GeneDx Holdings Corp. (WGS) reported revenue of $427.5 million (up 40.0% from FY2024) and a net loss of $21.0 million. Diluted EPS was -$0.73.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding GeneDx Holdings Corp. (WGS) shares worth $886.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Feeley Kevin on September 16, 2026 of 52 shares at $95.41 per share.
- In the last 90 days, WGS insiders reported 0 open-market purchases ($0) and 13 open-market sales ($1.8M) on Form 4, a net sale of $1.8M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $427.5M
- +40.0% vs prior year
- Insiders · 90 days
- 0 buys · 13 sells
- Net −$1.8M
- 13F holders
- 27 funds
- $886.7M · −3 vs prior quarter
- Latest 8-K
- Nov 18, 2026
- Item 5.02 · Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Provider of clinical exome and genome sequencing diagnostics powered by proprietary GeneDx Infinity™ rare disease dataset
- New emphasis on rapid and ultraRapid genomes, medium/long-read sequencing, and multimodal genomic analysis expansion in 2025
- Strategic shift: Accelerating industry leadership through integration of AI-powered variant interpretation and launching global market expansion with Fabric Genomics acquisition
- Quantitative metric: GeneDx Infinity™ dataset grew 30% in 2025, surpassing prior 24 years combined, includes 2.5M tests and 50% non-European genetic diversity
- Noteworthy fact: Leveraged AI (Multiscore) and cloud-based platforms to improve interpretation speed and scalability while lowering sequencing costs
Risk Factors
- Regulatory risk: $42M settlement agreement with third-party payor for alleged overpayments to Legacy Sema4, $2M remaining payments as of Dec 31, 2025
- Macroeconomic risk: reliance on reimbursement approvals from commercial and Medicaid payors, with 18% average reimbursement rate increase in 2025 impacting revenue
- Operational risk: dependency on third-party suppliers for diagnostic test components and data storage, affecting cost and service delivery efficiency
- Competitive risk: integration risk from Fabric Genomics acquisition to expand AI-enabled genome interpretation amid rapid technology evolution and competitors
- Financial risk: $57.2M non-cancellable operating leases and $29.2M finance leases creating fixed cash obligations impacting liquidity management
Management Discussion & Analysis
- Forward-looking statements noted, but no specific management guidance or risk details given
AI summary of the WGS 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New PAMA rate risk triggered by September 2026 preliminary weighted medians, with many codes facing reductions beginning January 1, 2027
- Most material update: cumulative PAMA cuts could continue through 2029, increasing aggregate financial impact over the phase-in period
- Regulatory risk: laboratories face substantial civil money penalties for failing to report or erroneously reporting private-payor data
- Revenue risk: Medicare coverage represents a significant patient base, making CMS reimbursement reductions especially impactful
- Policy uncertainty: Congress may enact the RESULTS Act or other PAMA reforms before January 1, 2027
Management Discussion & Analysis
- Q3 revenue $123.1M, up 5% YoY from $116.7M, driven by diagnostic test revenue of $120.1M
- Gross margin 69.9% vs 72.4% YoY, with net loss $12.3M vs $7.6M
- Best performer: whole exome and genome sequencing revenue up 12%, test volumes up 25%
- Cash and securities $170.1M; operating cash flow $(72.0)M vs $36.4M YoY
- Capital deployment: $150.0M Blackstone borrowing, $5.0M stock issuance, $21.8M property and software investment
AI summary of the WGS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CEO Katherine Stueland exits by December 15, 2026, remains Executive Advisor through January 31, 2027
- Everett Cunningham becomes CEO and Class II director, with a term through GeneDx’s 2029 annual meeting
Item 7.01: Regulation FD Disclosure
- Press release announces Mr. Cunningham’s appointment
- Ms. Stueland’s service ended, signaling a leadership transition
Item EX-99.1: Item EX-99.1
- Everett Cunningham appointed CEO and director by December 15, 2026, signaling a commercial-growth focus
- Katherine Stueland departing CEO and director after five-and-a-half years, remaining as adviser through January 31, 2027
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results announcement for quarter ended September 30, 2026
- Press release and earnings presentation furnished as Exhibits 99.1 and 99.2
Item EX-99.2: Item EX-99.2
- Q3 2026 revenue $123.1M, up from $114.4M sequentially, with exome/genome revenue reaching $110.4M
- Exome/genome volume 32,134, up 25% YoY, while accession volume grew 28%, signaling sustained demand
Item EX-99.1: Item EX-99.1
- Q3 revenue $123.1M, up 5% YoY, while exome/genome revenue reached $110.4M, up 12%
- Exome/genome volumes rose 25% to 32,134 tests, with accessions up 28%, supporting continued core-market demand
Item EX-99.1: Item EX-99.1
- Q2 revenue $114.4M, up 11% YoY, with exome/genome revenue $100.3M, up 17%
- Exome/genome volumes rose 32% YoY to 30,785 tests, supporting GeneDx’s shift toward higher-growth genomic testing
Item 2.02: Results of Operations and Financial Condition
- GeneDx scheduled fiscal Q2 2026 results disclosure for the quarter ended June 30, 2026
- Press release and earnings presentation furnished as Exhibits 99.1 and 99.2
AI summaries of WGS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for WGS
Don't miss the next WGS filing
- Alerts as it files. A push when WGS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut WGS, by share count.
- Ask anything. An AI agent that reads every WGS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Fuchs Thomas | M | Sep 17, 2026 | 1,146 | - |
| Fuchs Thomas | M | Sep 17, 2026 | 1,146 | - |
| Feeley Kevin | M | Sep 16, 2026 | 7,197 | - |
| Feeley Kevin | Sell | Sep 16, 2026 | 52 | $95.41 |
| Feeley Kevin | Sell | Sep 16, 2026 | 1,470 | $98.27 |
| Feeley Kevin | Sell | Sep 16, 2026 | 1,079 | $99.00 |
| Feeley Kevin | M | Sep 16, 2026 | 7,197 | - |
| Feeley Kevin | Sell | Sep 16, 2026 | 541 | $96.90 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $305.4M | $427.5M |
| Gross Profit | - | $194.4M | $298.2M |
| Operating Income | - | -$23.2M | -$13.1M |
| Net Income | - | -$52.3M | -$21.0M |
| Gross Margin | - | 63.6% | 69.7% |
| Op. Margin | - | -7.6% | -3.1% |
| Net Margin | - | -17.1% | -4.9% |
| Balance Sheet | |||
| Total Assets | - | $419.4M | $523.7M |
| Equity | - | $245.2M | $308.2M |
| ROE | - | -21.3% | -6.8% |
| Per Share | |||
| EPS | $-7.23 | $-1.94 | $-0.73 |
| Cash Flow | |||
| Operating CF | - | -$28.5M | $33.3M |
| CapEx | $5.3M | $5.5M | $19.0M |
Source: XBRL data in GeneDx Holdings Corp. (WGS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate WGS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $886.7M |
| Q2 2026 | 30 | $716.1M |
| Q1 2026 | 30 | $685.6M |
| Q4 2025 | 29 | $1.26B |
| Q3 2025 | 29 | $1.01B |
| Q2 2025 | 27 | $703.0M |
| Q1 2025 | 27 | $687.5M |
| Q4 2024 | 22 | $279.6M |
- Millennium Management+933.5K (+600%)
- D.E. Shaw & Co+634.7K (+1633%)
- Goldman Sachs Group+433.3K (+26%)
- ARK Investment Management+302.9K (+19%)
- JPMorgan Chase & Co+114.2K (+210%)
- Citadel Advisors LLC−196.8K (-23%)
- Franklin Resources−97.9K (-35%)
- Bank of America Corp−38.4K (-11%)
- Citigroup−20.1K (-37%)
- BlackRock−12.3K (-1%)
- Blackstone Group+79.9K
- Ameriprise Financial−207.7K
- Raymond James Financial−123.4K
- Principal Financial Group−69.2K
- FMR LLC (Fidelity)−7.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 221 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
WGS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 18, 2026 | - | Analysis | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| SC 13G | Aug 11, 2026 | - | - | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Jul 28, 2026 | - | - | |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
Related Health Care companies
- DCGO · DocGo Inc.Services-Health Services
- INNV · InnovAge Holding Corp.Services-Health Services
- LFST · LifeStance Health Group, Inc.Services-Health Services
- OMDA · Omada Health, Inc.Services-Health Services
- PNTG · Pennant Group, Inc.Services-Health Services
- PRVA · Privia Health Group, Inc.Services-Health Services
- SRTA · Strata Critical Medical, Inc.Services-Health Services
- TALK · Talkspace, Inc.Services-Health Services
WGS SEC filings: frequently asked questions
Are WGS insiders buying or selling?
In the last 90 days, GeneDx Holdings Corp. (WGS) officers, directors and 10% owners reported no open-market purchases and 13 open-market sales worth $1.8 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold WGS stock?
As of September 30, 2026, the largest GeneDx Holdings Corp. (WGS) holders among the 13F filers tracked by SignalX were Goldman Sachs Group ($152.0 million), ARK Investment Management ($138.3 million), BlackRock ($122.5 million), Millennium Management ($78.7 million), Morgan Stanley ($73.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was WGS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), GeneDx Holdings Corp. (WGS) reported revenue of $427.5 million (up 40.0% from FY2024) and a net loss of $21.0 million. Diluted EPS was -$0.73. The figures come from the XBRL data in the 10-K.
What are the main risks in WGS's latest 10-K?
In the 10-K filed February 23, 2026, GeneDx Holdings Corp. (WGS) flagged: Regulatory risk: $42M settlement agreement with third-party payor for alleged overpayments to Legacy Sema4, $2M remaining payments as of Dec 31, 2025. Macroeconomic risk: reliance on reimbursement approvals from commercial and Medicaid payors, with 18% average reimbursement rate increase in 2025 impacting revenue. (AI summary of the Risk Factors section.)
What did WGS report in its latest 8-K?
GeneDx Holdings Corp. (WGS) filed an 8-K on November 18, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers) and Item 7.01 (Regulation FD Disclosure). CEO Katherine Stueland exits by December 15, 2026, remains Executive Advisor through January 31, 2027.
What are the latest WGS SEC filings?
GeneDx Holdings Corp. (WGS) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 18, 2026 and a Form 4 insider filing on September 18, 2026.
What is WGS's SEC CIK number?
GeneDx Holdings Corp. (WGS)'s SEC Central Index Key (CIK) is 1818331. EDGAR lists every WGS filing under that number.
Ask anything about WGS
The research agent reads WGS's filings, financials, insider trades and 13F holders, then answers with sources.